Obesity Medicine

A recent study highlights the importance of medication adherence for significant weight loss and improved glycemic control in obesity treatment with GLP-1 agonists.

Monu Khanna, MD, discusses common medications, non-drug strategies, and holistic approaches to improve outcomes.

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Dr Khanna discusses dosing challenges, metabolic issues, and potential complications from medications like acetaminophen.

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

Obesity treatment evolves as GLP-1 medication use surges 587%, while bariatric surgery rates decline significantly. A new analysis parses the trends.

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Viking Therapeutics initiates phase 3 trials for VK2735, a promising dual incretin agonist targeting obesity and other metabolic disorders, based on strong phase 2 findings.

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

ADA 2025: The combination of the GLP-1 RA and novel monoclonal antibody yielded 92.8% of total weight loss from fat mass and 22.1% decrease in baseline weight.

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

ADA 2025: An intervention to emphasize weight-related care in primary care settings eliminated weight gain at the population level, researchers report.

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

Advances in obesity pharmacotherapy will be the focus of numerous late-breaking science sessions at ADA 2025; snapshots of 5 studies follow.

The ADA unveils the association's first Standards of Care for Overweight and Obesity, with a chapter on weight stigma and bias one of the first released.

The investigational dual GLP-1/GLP-2 agonist led to 11.6% weight loss over 28 weeks with no lifestyle changes, showing strong safety and tolerability in the trial.

The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right.

Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.

Your daily dose of the clinical news you may have missed.

High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.

Novel guidelines include specific strategies that support the prescription, implementation, and monitoring of lifestyle changes to reach glycemic control and, possibly, disease remission.

Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.

When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.